SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Monday reported a loss of $7.9 million in its fourth quarter.
The Salt Lake City-based company said it had a loss of 8 cents per share. Earnings, adjusted for costs related to mergers and acquisitions and asset impairment costs, came to 4 cents per share.
The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 2 cents per share.
The molecular diagnostic company posted revenue of $209.8 million in the period.
For the year, the company reported a loss of $365.9 million, or $3.95 per share. Revenue was reported as $824.5 million.
Myriad expects full-year revenue in the range of $860 million to $880 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at https://www.zacks.com/ap/MYGN
Copyright © 2026 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
